U.S. Markets open in 35 mins.

AEMD Attracts More Financing

Zacks Equity Research

AEMD Attracts More Financing

Brian Marckx, CFA

Aethlon Medical (AEMD) continues to attract financing to fund development of their Hemopurifier, reflecting ongoing investor interest.  Since the beginning of the current year Aethlon has raised over $1.6 million in new financing, the most recent of which came in mid-June from the sale of 8.22 million shares of common stock at $0.072/share (80% of the most recent avg 5-day closing price) for gross proceeds of $592k.  The investor also received seven-year warrants to purchase 4.1 million common shares for $0.109 (120% premium to the most recent avg 5-day closing price).  

To access a free copy of the full research report, please visit Brian Marckx's coverage page at scr.zacks.com.

Read the Full Research Report on AEMD

Zacks Investment Research

More From Zacks.com